Xin Lang Ji Jin·2025-08-07 02:24Core Viewpoint - The medical sector in A-shares is experiencing a resurgence, with the largest medical ETF (512170) rising by 2% in early trading on August 7, 2023, and quickly surpassing a transaction volume of 400 million yuan [1]. Group 1: Market Performance - The medical device sector is leading the gains, with stocks like Furuide (福瑞股份) rising nearly 8%, and Huada Zhizao (华大智造) and Yingke Medical (英科医疗) increasing over 6% [1]. - The CXO sector is underperforming, with WuXi AppTec (药明康德) and Zhaoyan New Drug (昭衍新药) both declining by over 1% [1]. Group 2: Industry Trends - The 11th batch of national drug procurement has officially started, involving 55 products that are all mature and competitive, with an emphasis on optimizing procurement rules and adhering to the principle of "anti-involution" [1]. - Citic Securities reports that recent high-level discussions have emphasized principles such as "anti-involution" and "procurement optimization not solely based on low prices," signaling a turning point for the innovative drug and medical device industry [3]. - Citic Jin Investment highlights that increasing international business opportunities in the medical device sector are expected to drive high growth for several companies by 2025, leading to a potential revaluation of these companies [3]. Group 3: Investment Opportunities - Some fund managers believe that the market trend this year may favor medical devices after pharmaceuticals, suggesting that the previously underperforming medical device sector may see a rebound [3]. - The largest medical ETF (512170) is recommended for capturing upward opportunities in the medical device and CXO sectors, focusing on "medical devices + medical services" and being highly correlated with AI medical applications [3].